Globally, Pharmacovigilance (PV) is built on one central idea: the benefit–risk evaluation should not stop at approval; it must continue through the full drug development regulatory process and the product’s commercial lifecycle. It is no
Read MoreIn Europe, Pharmacovigilance is heavily dependent on submitted documents. Each core submission enables regulators to assess how data has been maintained throughout the product life cycle. This approach minimizes risks. A robust safety system can
Read MoreThe pharmacovigilance (PV) landscape is evolving rapidly, triggered by increasing data volumes, global collaborative efforts, and demanding data transparency expectations. Given the scenario, 2026 is expected to become a defining year for the Pharmaceutical industry
Read More